On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...

FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade Safety results in all LIBERTY-CUPID Phase 3 trials were generally consistent with ...

Please provide your email address to receive an email when new articles are posted on . Urticaria patients taking Dupixent experienced an 8.64-point reduction in itch and 15.86-point reduction in ...

Hives (urticaria) are raised, itchy bumps on your skin. If you get itchy hives that come and go mostly every day for over six weeks, you might have a skin condition known as chronic spontaneous ...

Sanofi (SNY) and Regeneron’s (REGN) Dupixent has gained EU approval as the first targeted therapy in more than ten years for chronic spontaneous urticaria, offering a new option for patients who do ...

Please provide your email address to receive an email when new articles are posted on . The resubmission included new data from a phase 3 program which showed Dupixent reduced itchiness and hives. The ...

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing ...

The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in patients aged 12 and older who remain symptomatic despite antihistamine treatment ...

Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...